sorafenib — Medica
Differentiated thyroid carcinoma
Initial criteria
- age ≥ 18 years
- ONE of the following:
- papillary or follicular thyroid carcinoma AND disease refractory to radioactive iodine therapy
- oncocytic (formerly Hürthle cell) carcinoma
Approval duration
1 year